JP7894113B2 - 治療用金属錯体およびリガンドならびにその作成および使用の方法 - Google Patents

治療用金属錯体およびリガンドならびにその作成および使用の方法

Info

Publication number
JP7894113B2
JP7894113B2 JP2020512506A JP2020512506A JP7894113B2 JP 7894113 B2 JP7894113 B2 JP 7894113B2 JP 2020512506 A JP2020512506 A JP 2020512506A JP 2020512506 A JP2020512506 A JP 2020512506A JP 7894113 B2 JP7894113 B2 JP 7894113B2
Authority
JP
Japan
Prior art keywords
compound
aliphatic
copper
day
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020512506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532538A (ja
JP2020532538A5 (enExample
Inventor
ビュードライ クリス
ハースト ジェームス
ベックマン ジョセフ
シロイス ジョン
Original Assignee
オレゴン ステイト ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレゴン ステイト ユニバーシティー filed Critical オレゴン ステイト ユニバーシティー
Publication of JP2020532538A publication Critical patent/JP2020532538A/ja
Publication of JP2020532538A5 publication Critical patent/JP2020532538A5/ja
Priority to JP2023160601A priority Critical patent/JP2024001064A/ja
Priority to JP2025187943A priority patent/JP2026041735A/ja
Application granted granted Critical
Publication of JP7894113B2 publication Critical patent/JP7894113B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/08—Copper compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020512506A 2017-09-01 2018-08-31 治療用金属錯体およびリガンドならびにその作成および使用の方法 Active JP7894113B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023160601A JP2024001064A (ja) 2017-09-01 2023-09-25 治療用金属錯体およびリガンドならびにその作成および使用の方法
JP2025187943A JP2026041735A (ja) 2017-09-01 2025-11-07 治療用金属錯体およびリガンドならびにその作成および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553714P 2017-09-01 2017-09-01
US62/553,714 2017-09-01
PCT/US2018/049163 WO2019046761A1 (en) 2017-09-01 2018-08-31 THERAPEUTIC METAL COMPLEXES AND LIGANDS, METHODS OF MAKING AND USING SAME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023160601A Division JP2024001064A (ja) 2017-09-01 2023-09-25 治療用金属錯体およびリガンドならびにその作成および使用の方法

Publications (3)

Publication Number Publication Date
JP2020532538A JP2020532538A (ja) 2020-11-12
JP2020532538A5 JP2020532538A5 (enExample) 2021-10-07
JP7894113B2 true JP7894113B2 (ja) 2026-07-23

Family

ID=63684510

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020512506A Active JP7894113B2 (ja) 2017-09-01 2018-08-31 治療用金属錯体およびリガンドならびにその作成および使用の方法
JP2023160601A Pending JP2024001064A (ja) 2017-09-01 2023-09-25 治療用金属錯体およびリガンドならびにその作成および使用の方法
JP2025187943A Pending JP2026041735A (ja) 2017-09-01 2025-11-07 治療用金属錯体およびリガンドならびにその作成および使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023160601A Pending JP2024001064A (ja) 2017-09-01 2023-09-25 治療用金属錯体およびリガンドならびにその作成および使用の方法
JP2025187943A Pending JP2026041735A (ja) 2017-09-01 2025-11-07 治療用金属錯体およびリガンドならびにその作成および使用の方法

Country Status (8)

Country Link
US (2) US11596651B2 (enExample)
EP (1) EP3676271A1 (enExample)
JP (3) JP7894113B2 (enExample)
CN (1) CN111278835A (enExample)
AU (1) AU2018325283B2 (enExample)
CA (1) CA3074258A1 (enExample)
IL (1) IL272895B2 (enExample)
WO (1) WO2019046761A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7894113B2 (ja) * 2017-09-01 2026-07-23 オレゴン ステイト ユニバーシティー 治療用金属錯体およびリガンドならびにその作成および使用の方法
EP4003361A1 (en) * 2019-07-25 2022-06-01 ALS Therapy Development Institute Cuptsm for the treatment of neurodegenerative disorders
CN116234800A (zh) * 2020-08-26 2023-06-06 Als治疗发展学会 用于治疗神经退行性病症的铜络合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061306A1 (en) 2006-11-20 2008-05-29 The University Of Melbourne Metal delivery agents and therapeutic uses of the same
JP2012511513A (ja) 2008-12-12 2012-05-24 ザ ユニバーシティ オブ メルボルン 非対称性ビス（チオセミカルバゾン）の調製方法
JP2016540828A (ja) 2013-11-11 2016-12-28 コラボレイティブ メディシナル デベロップメント， エルエルシー 金属錯体および処置方法
WO2017070752A1 (en) 2015-10-29 2017-05-04 The University Of Queensland Imaging agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7403524A (en) 1959-09-15 1974-05-27 Pharmaceutical compsn. - contg. alpha-dithiosemicarbazone active against trichomonas vaginalis
US4107210A (en) 1976-09-07 1978-08-15 The Dow Chemical Company Synthesis of alpha-diketones
CA2166676C (en) * 1995-01-09 2007-05-01 Yasuhisa Fujibayashi Diagnostic agent for hypoxia or mitochondrial dysfunction comprising radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative
GB0617299D0 (en) * 2006-09-01 2006-10-11 Isis Innovation Compounds for imaging and therapy
WO2017214546A1 (en) * 2016-06-10 2017-12-14 University Of Louisville Research Foundation, Inc. Compounds, related compositions, catalysts, electrochemical cells, fuel cells, their preparation and their uses
WO2018204564A1 (en) * 2017-05-04 2018-11-08 University Of Louisville Research Foundation, Inc. Thiosemicarbazone derivatives as anti-cancer agents
JP7894113B2 (ja) * 2017-09-01 2026-07-23 オレゴン ステイト ユニバーシティー 治療用金属錯体およびリガンドならびにその作成および使用の方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061306A1 (en) 2006-11-20 2008-05-29 The University Of Melbourne Metal delivery agents and therapeutic uses of the same
JP2012511513A (ja) 2008-12-12 2012-05-24 ザ ユニバーシティ オブ メルボルン 非対称性ビス（チオセミカルバゾン）の調製方法
JP2016540828A (ja) 2013-11-11 2016-12-28 コラボレイティブ メディシナル デベロップメント， エルエルシー 金属錯体および処置方法
WO2017070752A1 (en) 2015-10-29 2017-05-04 The University Of Queensland Imaging agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Bioelectrochemistry and Bioenergetics, (1999), 48, pp.109-116
Chem. Commun., (1998), pp.2531-2532
Dalton Transactions, (2007), pp.209-217
Inorganic Chemistry, (2015), 54, pp.9556-9567
Inorganica Chimica Acta, (2005), 358, pp.2770-2780
Organic Mass Spectrometry, (1971), Vol.5, pp.15-18
RADIOISOTOPES, (1986), 35, pp.249-255

Also Published As

Publication number Publication date
EP3676271A1 (en) 2020-07-08
US12403159B2 (en) 2025-09-02
JP2026041735A (ja) 2026-03-10
IL272895B1 (en) 2025-02-01
JP2020532538A (ja) 2020-11-12
CN111278835A (zh) 2020-06-12
AU2018325283B2 (en) 2023-11-16
CA3074258A1 (en) 2019-03-07
US20230172977A1 (en) 2023-06-08
US20200188430A1 (en) 2020-06-18
AU2018325283A1 (en) 2020-03-12
US11596651B2 (en) 2023-03-07
IL272895B2 (en) 2025-06-01
IL272895A (en) 2020-04-30
JP2024001064A (ja) 2024-01-09
WO2019046761A1 (en) 2019-03-07

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230927

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231016

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260703

R150 Certificate of patent or registration of utility model

Ref document number: 7894113

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150